Cargando…

The Frequency of and Risk Factors for the Use of Bisphosphonates in the Adjuvant Setting of Primary Breast Cancer in Germany

PURPOSE: The aim of this cross-sectional health care study (use of bisphosphonates in primary tumors of the mammae, EBisMa) is to determine how often bisphosphonate medication is used in patients with non-metastatic primary breast cancer treatment, but who do not suffer from osteoporosis. Furthermor...

Descripción completa

Detalles Bibliográficos
Autores principales:	Fick, Eva-Maria, Katalinic, Alexander, Waldmann, Annika
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Korean Cancer Association 2015
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4614212/ https://www.ncbi.nlm.nih.gov/pubmed/25672584 http://dx.doi.org/10.4143/crt.2014.099

Ejemplares similares

Long-term Incidence and Mortality Trends for Breast Cancer in Germany
por: Hübner, Joachim, et al.
Publicado: (2020)

Temporal trends in age- and stage-specific incidence of colorectal adenocarcinomas in Germany
por: Waldmann, Annika, et al.
Publicado: (2023)

Bisphosphonates in the adjuvant treatment of early breast cancer
por: Gnant, M
Publicado: (2009)

Sleep quality and health-related quality of life among long-term survivors of (non-) Hodgkin lymphoma in Germany
por: Hammersen, Friederike, et al.
Publicado: (2017)

Measuring prostate-specific quality of life in prostate cancer patients scheduled for radiotherapy or radical prostatectomy and reference men in Germany and Canada using the Patient Oriented Prostate Utility Scale-Psychometric (PORPUS-P)
por: Waldmann, Annika, et al.
Publicado: (2009)

Imputation of missing values of tumour stage in population-based cancer registration
por: Eisemann, Nora, et al.
Publicado: (2011)

Normative Data of the EORTC QLQ-C30 For the German Population: A Population-Based Survey
por: Waldmann, Annika, et al.
Publicado: (2013)

Bisphosphonates in the Adjuvant Setting of Breast Cancer Therapy—Effect on Survival: A Systematic Review and Meta-Analysis
por: Ben-Aharon, Irit, et al.
Publicado: (2013)

The population-based oncological health care study OVIS – recruitment of the patients and analysis of the non-participants
por: Pritzkuleit, Ron, et al.
Publicado: (2008)

Should all adjuvant breast cancer patients receive a bisphosphonate?
por: Cameron, David A
Publicado: (2003)

The role of bisphosphonates in breast cancer: Development of bisphosphonates
por: Fleisch, Herbert
Publicado: (2002)

Young Adult German Breast Cancer Patients Participating in a Three-Week Inpatient Mother–Child Rehab Program Have High Needs for Supportive Care
por: Hammersen, Friederike, et al.
Publicado: (2023)

Adjuvant bisphosphonate use in patients with early stage breast cancer: a physician survey
por: McGee, Sharon, et al.
Publicado: (2021)

Different Aspects of Self-Reported Quality of Life in 450 German Melanoma Survivors
por: Waldmann, Annika, et al.
Publicado: (2011)

The ProCaSP study: quality of life outcomes of prostate cancer patients after radiotherapy or radical prostatectomy in a cohort study
por: Eisemann, Nora, et al.
Publicado: (2015)

The role of bisphosphonates in breast cancer: Direct effects of bisphosphonates on breast cancer cells
por: Senaratne, Siddhika G, et al.
Publicado: (2002)

The role of bisphosphonates in breast cancer: Actions of bisphosphonates in animal models of breast cancer
por: Padalecki, Susan S, et al.
Publicado: (2002)

Bisphosphonates in the adjuvant treatment of cancer: experimental evidence and first clinical results
por: Diel, I J, et al.
Publicado: (2000)

The role of bisphosphonates in breast cancer: The present and future role of bisphosphonates in the management of patients with breast cancer
por: Brown, Janet E, et al.
Publicado: (2002)

Risks and benefits of bisphosphonates
por: Coleman, R E
Publicado: (2008)

Managing bone mineral density with oral bisphosphonate therapy in women with breast cancer receiving adjuvant aromatase inhibition
por: Van Poznak, Catherine
Publicado: (2010)

Contributing and limiting factors to guideline-adherent therapy in senior and elderly breast cancer patients: a questionnaire-based cross-sectional study using clinical and cancer registry data in Germany
por: Heidenreich, Andreas, et al.
Publicado: (2023)

Oral cancer awareness campaign in Northern Germany: first positive trends in incidence and tumour stages
por: Hertrampf, Katrin, et al.
Publicado: (2020)

Bisphosphonates for osteoporosis treatment are associated with reduced breast cancer risk
por: Newcomb, P A, et al.
Publicado: (2010)

Adjuvant bisphosphonate treatment for breast cancer: Where are we heading and can the pre-clinical literature help us get there?
por: Russell, Kent, et al.
Publicado: (2012)

Adjuvant bisphosphonate use in patients with early stage breast cancer: Patient perspectives on treatment acceptability and potential de-escalation
por: McGee, Sharon, et al.
Publicado: (2021)

Skin cancer screening participation and impact on melanoma incidence in Germany – an observational study on incidence trends in regions with and without population-based screening
por: Waldmann, A, et al.
Publicado: (2012)

Primary Sjogren syndrome increases the risk of bisphosphonate-related osteonecrosis of the jaw
por: Kuo, Pei-I, et al.
Publicado: (2021)

Real-world use of denosumab and bisphosphonates in patients with solid tumours and bone metastases in Germany
por: Diel, Ingo, et al.
Publicado: (2020)

Off-trial evaluation of bisphosphonates in patients with metastatic breast cancer
por: Liauw, Winston, et al.
Publicado: (2005)

Bisphosphonates and primary breast cancer risk: an updated systematic review and meta-analysis involving 963,995 women
por: Liu, Yupeng, et al.
Publicado: (2019)

Association of Antiosteoporotic Medication Bisphosphonates and Denosumab with Primary Breast Cancer: An Electronic Health Record Cohort Study
por: Stanoyevitch, Alexander, et al.
Publicado: (2021)

Evaluation of pharmaceutical concerns in Germany: frequency and potential reasons
por: Gradl, Gabriele, et al.
Publicado: (2016)

Association Use of Bisphosphonates with Risk of Breast Cancer: A Meta-Analysis
por: Peng, Rui, et al.
Publicado: (2020)

A population-based comparison of second primary cancers in Germany and Sweden between 1997 and 2006: clinical implications and etiologic aspects
por: Liu, Hao, et al.
Publicado: (2013)

Validation of the German version of the Family Reported Outcome Measure (FROM-16) to assess the impact of disease on the partner or family member
por: Elsner, Susanne A., et al.
Publicado: (2021)

Are adjuvant bisphosphonates now standard of care of women with early stage breast cancer? A debate from the Canadian Bone and the Oncologist New Updates meeting
por: Jacobs, Carmel, et al.
Publicado: (2015)

Effect of adjuvant bisphosphonates on disease-free survival in early breast cancer: Retrospective analysis results in an unselected single-center cohort
por: Hadji, Peyman, et al.
Publicado: (2013)

Compliance and patient reported toxicity from oral adjuvant bisphosphonates in patients with early breast cancer. A cross sectional study
por: Wilson, C., et al.
Publicado: (2019)

Optimizing dosing frequencies for bisphosphonates in the management of postmenopausal osteoporosis: patient considerations
por: Sunyecz, John
Publicado: (2008)

Cannot write session to /tmp/vufind_sessions/sess_sj2p1q4a99jf7lgm9e2i9peasp